Show simple item record

dc.contributor.advisorIbáñez-Pinilla, Milcíades 
dc.contributor.advisorVallejo Silva, Alexie 
dc.creatorRodríguez T., María del Rosario 
dc.creatorMéndez Álvarez, Liliana P. 
dc.creatorJairo M., González Díaz 
dc.date.accessioned2016-03-07T22:23:26Z
dc.date.available2016-03-07T22:23:26Z
dc.date.created2016-02-01
dc.date.issued2016 
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/11837
dc.descriptionINTRODUCCIÓN: El 80% de los niños y adolescentes con trastornos del espectro autista (TEA) presenta algún trastorno del sueño, en cuya génesis al parecer intervienen alteraciones en la regulación de la melatonina. El objetivo de este metaanálisis fue determinar la eficacia y seguridad de la melatonina para el manejo de ciertos trastornos del sueño en niños con TEA. MÉTODOS: Tres revisores extrajeron los datos relevantes de los ensayos clínicos aleatorizados doble ciego de alta calidad publicados en bases de datos primarias, de ensayos clínicos, de revisiones sistemáticas y de literatura gris; además se realizó búsqueda en bola de nieve. Se analizaron los datos con RevMan 5.3. Se realizó un análisis del inverso de la varianza por un modelo de efectos aleatorios para las diferencias de medias de los desenlaces propuestos: duración del tiempo total, latencia de sueño y número de despertares nocturnos. Se evaluó la heterogeneidad interestudios con el parámetro I2 RESULTADOS: La búsqueda inicial arrojó 355 resultados, de los cuales tres cumplieron los criterios de selección. La melatonina resultó ser un medicamento seguro y eficaz para aumentar la duración total del sueño y disminuir la latencia de sueño en niños y adolescentes con TEA; hasta el momento la evidencia sobre el número de despertares nocturnos no es estadísticamente significativa. DISCUSIÓN: A la luz de la evidencia disponible, la melatonina es una elección segura y eficaz para el manejo de ciertos problemas del sueño en niños y adolescentes con TEA. Es necesario realizar estudios con mayores tamaños muestrales y comparados con otros medicamentos disponibles en el mercado.
dc.description.abstractINTRODUCTION: Up to 80% of children and adolescents with autism spectrum disorders (ASD) has a sleep disorder, in whose genesis some alterations in the regulation of melatonin are apparently involved. The aim of this meta-analysis was to determine the efficacy and safety of melatonin for management of certain sleep disorders in children with ASD. METHODS: Three reviewers extracted relevant data from high-quality double-blind randomized clinical trials published in primary, clinical trials, systematic reviews and gray literature databases; further search was conducted in snowball. Data were analyzed with RevMan 5.3. An inverse of variance analysis by random-effects model was made for the mean differences of the proposed outcomes was performed (total sleep time, sleep onset latency and number of nighttime awakenings). Inter-study heterogeneity was evaluated with I2 parameter. RESULTS: The initial search yielded 355 results, of which three met the selection criteria. Melatonin was found to be a safe and effective drug to increase total sleep time and decrease sleep onset latency in children and adolescents with ASD; so far the evidence on the number of night awakenings is not statistically significant. DISCUSSION: According to available evidence, melatonin is a safe and effective choice for managing certain sleep problems in children and adolescents with ASD. Studies are needed with larger sample sizes and comparing with other drugs available in the market.
dc.description.sponsorshipNo aplica
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.sourcereponame:Repositorio Institucional EdocUR
dc.sourceinstname:Universidad del Rosario
dc.subjectAutismo
dc.subjectMelatonina
dc.subjectTrastornos del Sueño
dc.subject.ddcEnfermedades 
dc.subject.lembPsiquiatría
dc.titleEficacia y seguridad de la melatonina para el manejo de los trastornos del sueño en el autismo: meta-análisis
dc.typebachelorThesis
dc.publisherUniversidad del Rosario
dc.creator.degreeEspecialista en Psiquiatría
dc.publisher.programEspecialización en Psiquiatría
dc.publisher.departmentFacultad de Medicina
dc.subject.keywordAutism
dc.subject.keywordMelatonin
dc.subject.keywordSleep Disorders
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.subject.decsPsicoanálisis
dc.subject.decsTrastorno autístico
dc.subject.decsTrastornos del sueño
dc.subject.decsMelatonina
dc.type.spaTrabajo de grado
dc.rights.accesoAbierto (Texto completo)
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.source.bibliographicCitationReszka SS, Boyd BA, McBee M, Hume KA, Odom SL. Brief report: concurrent validity of autism symptom severity measures. J Autism Dev Disord. Springer; 2014;44(2):466–70.
dc.source.bibliographicCitationNazeer A, Ghaziuddin M. Autism spectrum disorders: clinical features and diagnosis. Pediatr Clin North Am. Elsevier; 2012;59(1):19–25.
dc.source.bibliographicCitationLee YJ, Oh SH, Park C, Hong M, Lee AR, Yoo HJ, et al. Advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder. Clin Psychopharmacol Neurosci. Korea (South); 2014 Apr;12(1):19–30.
dc.source.bibliographicCitationAman MG, Lam KSL, Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord. United States; 2003 Oct;33(5):527–34.
dc.source.bibliographicCitationKotagal S, Broomall E. Sleep in children with autism spectrum disorder. Pediatr Neurol. Elsevier; 2012;47(4):242–51.
dc.source.bibliographicCitationMelke J. The role of melatonin in autism spectrum disorders. Scand Neuropsychopharmacol. 2009;2(1).
dc.source.bibliographicCitationTordjman S, Najjar I, Bellissant E, Anderson GM, Barburoth M, Cohen D, et al. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci. Multidisciplinary Digital Publishing Institute; 2013;14(10):20508–42.
dc.source.bibliographicCitationCenters for Disease Control and Prevention. Autism Spectrum Disorder (ASD) [Internet]. 2015 [cited 2015 Oct 10]. Available from: http://www.cdc.gov/ncbddd/autism/data.html
dc.source.bibliographicCitationAllik H, Larsson J-O, Smedje H. Sleep patterns in school-age children with Asperger syndrome or high-functioning autism: a follow-up study. J Autism Dev Disord. United States; 2008 Oct;38(9):1625–33.
dc.source.bibliographicCitationGiannotti F, Cortesi F, Cerquiglini A, Miraglia D, Vagnoni C, Sebastiani T, et al. An investigation of sleep characteristics, EEG abnormalities and epilepsy in developmentally regressed and non-regressed children with autism. J Autism Dev Disord. United States; 2008 Nov;38(10):1888–97
dc.source.bibliographicCitationLiu X, Hubbard JA, Fabes RA, Adam JB. Sleep disturbances and correlates of children with autism spectrum disorders. Child Psychiatry Hum Dev. United States; 2006;37(2):179–91.
dc.source.bibliographicCitationBarnevik Olsson M, Carlsson LH, Westerlund J, Gillberg C, Fernell E. Autism before diagnosis: crying, feeding and sleeping problems in the first two years of life. Acta Paediatr. Norway; 2013 Jun;102(6):635–9.
dc.source.bibliographicCitationMayes SD, Calhoun SL. Variables related to sleep problems in children with autism. Res Autism Spectr Disord. Elsevier; 2009;3(4):931–41.
dc.source.bibliographicCitationMiano S, Bruni O, Elia M, Trovato A, Smerieri A, Verrillo E, et al. Sleep in children with autistic spectrum disorder: a questionnaire and polysomnographic study. Sleep Med. Netherlands; 2007 Dec;9(1):64–70.
dc.source.bibliographicCitationHodge D, Carollo TM, Lewin M, Hoffman CD, Sweeney DP. Sleep patterns in children with and without autism spectrum disorders: developmental comparisons. Res Dev Disabil. United States; 2014 Jul;35(7):1631–8.
dc.source.bibliographicCitationGoldman SE, Richdale AL, Clemons T, Malow BA. Parental sleep concerns in autism spectrum disorders: variations from childhood to adolescence. J Autism Dev Disord. United States; 2012 Apr;42(4):531–8.
dc.source.bibliographicCitationMalow BA, Byars K, Johnson K, Weiss S, Bernal P, Goldman SE, et al. A practice pathway for the identification, evaluation, and management of insomnia in children and adolescents with autism spectrum disorders. Pediatrics. United States; 2012 Nov;130 Suppl :S106–24.
dc.source.bibliographicCitationGoldman SE, McGrew S, Johnson KP, Richdale AL, Clemons T, Malow BA. Sleep is associated with problem behaviors in children and adolescents with autism spectrum disorders. Res Autism Spectr Disord. Elsevier; 2011;5(3):1223–9.
dc.source.bibliographicCitationDeVincent CJ, Gadow KD, Delosh D, Geller L. Sleep disturbance and its relation to DSM-IV psychiatric symptoms in preschool-age children with pervasive developmental disorder and community controls. J Child Neurol. Canada; 2007 Feb;22(2):161–9.
dc.source.bibliographicCitationSikora DM, Johnson K, Clemons T, Katz T. The relationship between sleep problems and daytime behavior in children of different ages with autism spectrum disorders. Pediatrics. United States; 2012 Nov;130 Suppl :S83–90.
dc.source.bibliographicCitationPatzold LM, Richdale AL, Tonge BJ. An investigation into sleep characteristics of children with autism and Asperger’s Disorder. J Paediatr Child Health. AUSTRALIA; 1998 Dec;34(6):528– 33.
dc.source.bibliographicCitationHodge D, Hoffman CD, Sweeney DP, Riggs ML. Relationship between children’s sleep and mental health in mothers of children with and without autism. J Autism Dev Disord. United States; 2013 Apr;43(4):956–63.
dc.source.bibliographicCitationVriend JL, Corkum P V, Moon EC, Smith IM. Behavioral interventions for sleep problems in children with autism spectrum disorders: current findings and future directions. J Pediatr Psychol. United States; 2011 Oct;36(9):1017–29.
dc.source.bibliographicCitationRossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and metaanalysis. Dev Med Child Neurol. England; 2011 Sep;53(9):783–92.
dc.source.bibliographicCitationKanner L. Autistic disturbances of affective contact. Nerv Child. 1943;
dc.source.bibliographicCitationAsperger H. Die „Autistischen Psychopathen” im Kindesalter. Eur Arch Psychiatry Clin Neurosci. Springer; 1944;117(1):76–136.
dc.source.bibliographicCitationWing L. Asperger’s syndrome: a clinical account. Psychol Med. Cambridge Univ Press; 1981;11(01):115–29.
dc.source.bibliographicCitationRutter M. Diagnosis and definition of childhood autism. J Autism Child Schizophr. Springer; 1978;8(2):139–61.
dc.source.bibliographicCitationAmerican Psychiatric Association. Diagnostic and statistical manual of mental disorders. American Psychiatric Publishing; 2013.
dc.source.bibliographicCitationFombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res. Nature Publishing Group; 2009;65(6):591–8.
dc.source.bibliographicCitationDuchan E, Patel DR. Epidemiology of autism spectrum disorders. Pediatr Clin North Am. Elsevier; 2012;59(1):27–43.
dc.source.bibliographicCitationFisch GS. Nosology and epidemiology in autism: classification counts. Am J Med Genet C Semin Med Genet. United States; 2012 May;160C(2):91–103.
dc.source.bibliographicCitationElsabbagh M, Divan G, Koh Y-J, Kim YS, Kauchali S, Marcin C, et al. Global prevalence of autism and other pervasive developmental disorders. Autism Res. United States; 2012 Jun;5(3):160–79.
dc.source.bibliographicCitationHultman CM, Sandin S, Levine SZ, Lichtenstein P, Reichenberg A. Advancing paternal age and risk of autism: new evidence from a population-based study and a meta-analysis of epidemiological studies. Mol Psychiatry. England; 2011 Dec;16(12):1203–12.
dc.source.bibliographicCitationKong A, Frigge ML, Masson G, Besenbacher S, Sulem P, Magnusson G, et al. Rate of de novo mutations and the importance of father’s age to disease risk. Nature. England; 2012
dc.source.bibliographicCitationGardener H, Spiegelman D, Buka SL. Prenatal risk factors for autism: comprehensive metaanalysis. Br J Psychiatry. England; 2009 Jul;195(1):7–14.
dc.source.bibliographicCitationRoberts EM, English PB, Grether JK, Windham GC, Somberg L, Wolff C. Maternal residence near agricultural pesticide applications and autism spectrum disorders among children in the California Central Valley. Environ Health Perspect. United States; 2007 Oct;115(10):1482–9.
dc.source.bibliographicCitationHowlin P, Moss P, Savage S, Rutter M. Social outcomes in mid- to later adulthood among individuals diagnosed with autism and average nonverbal IQ as children. J Am Acad Child Adolesc Psychiatry. United States; 2013 Jun;52(6):572–81.e1.
dc.source.bibliographicCitationJohnson CP, Myers SM. Identification and evaluation of children with autism spectrum disorders. Pediatrics. Am Acad Pediatrics; 2007;120(5):1183–215.
dc.source.bibliographicCitationRogers SJ. What are infant siblings teaching us about autism in infancy? Autism Res. United States; 2009 Jun;2(3):125–37.
dc.source.bibliographicCitationVia E, Radua J, Cardoner N, Happe F, Mataix-Cols D. Meta-analysis of gray matter abnormalities in autism spectrum disorder: should Asperger disorder be subsumed under a broader umbrella of autistic spectrum disorder? Arch Gen Psychiatry. United States; 2011 Apr;68(4):409–18.
dc.source.bibliographicCitationRadua J, Via E, Catani M, Mataix-Cols D. Voxel-based meta-analysis of regional white-matter volume differences in autism spectrum disorder versus healthy controls. Psychol Med. England; 2011 Jul;41(7):1539–50.
dc.source.bibliographicCitationPhilip RCM, Dauvermann MR, Whalley HC, Baynham K, Lawrie SM, Stanfield AC. A systematic review and meta-analysis of the fMRI investigation of autism spectrum disorders. Neurosci Biobehav Rev. United States; 2012 Feb;36(2):901–42.
dc.source.bibliographicCitationAmaral DG, Schumann CM, Nordahl CW. Neuroanatomy of autism. Trends Neurosci. Elsevier; 2008;31(3):137–45.
dc.source.bibliographicCitationPardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry. England; 2005 Dec;17(6):485–95.
dc.source.bibliographicCitationRonald A, Hoekstra RA. Autism spectrum disorders and autistic traits: a decade of new twin studies. Am J Med Genet B Neuropsychiatr Genet. United States; 2011 Apr;156B(3):255–74.
dc.source.bibliographicCitationBanerjee S, Riordan M, Bhat MA. Genetic aspects of autism spectrum disorders: insights from animal models. Front Cell Neurosci. Switzerland; 2014;8:58.
dc.source.bibliographicCitationBrentani H, Paula CS de, Bordini D, Rolim D, Sato F, Portolese J, et al. Autism spectrum disorders: an overview on diagnosis and treatment. Rev Bras Psiquiatr. Brazil; 2013;35 Suppl 1:S62–72.
dc.source.bibliographicCitationAkins RS, Angkustsiri K, Hansen RL. Complementary and alternative medicine in autism: an evidence-based approach to negotiating safe and efficacious interventions with families. Neurotherapeutics. United States; 2010 Jul;7(3):307–19.
dc.source.bibliographicCitationLerner AB, Case JD, Takahashi Y, Lee TH, Mori W. Isolation of melatonin, the pineal gland factor that lightens melanocyteS1. J Am Chem Soc. ACS Publications; 1958;80(10):2587.
dc.source.bibliographicCitationMalenka RC, Nestler EJ, Hyman SE, Sydor A, Brown RY. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. New York: McGrawHill Medical. Book; 2009.
dc.source.bibliographicCitationReiter RJ. The melatonin rhythm: both a clock and a calendar. Experientia. Springer; 1993;49(8):654–64.
dc.source.bibliographicCitationDubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci. United States; 2003 Sep;8:d1093–108
dc.source.bibliographicCitationCarocci A, Catalano A, Sinicropi MS. Melatonergic drugs in development. Clin Pharmacol Adv Appl. Dove Press; 2014;6:127.
dc.source.bibliographicCitationDe Leersnyder H, Zisapel N, Laudon M. Prolonged-release melatonin for children with neurodevelopmental disorders. Pediatr Neurol. Elsevier; 2011;45(1):23–6.
dc.source.bibliographicCitationIllnait-Ferrer J. Melatonina: actualidad de una hormona olvidada Melatonin: the actuality of a forgotten hormone. Rev CENIC Ciencias Biológicas. 2012;43(3).
dc.source.bibliographicCitationJadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. Elsevier; 1996;17(1):1–12.
dc.source.bibliographicCitationHiggins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Wiley Online Library; 2008.
dc.source.bibliographicCitationHiggins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ Br Med J. BMJ Group; 2003;327(7414):557.
dc.source.bibliographicCitationCortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res. England; 2012
dc.source.bibliographicCitationGarstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev. England; 2006 Sep;32(5):585–9.
dc.source.bibliographicCitationWright B, Sims D, Smart S, Alwazeer A, Alderson-Day B, Allgar V, et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disord. United States; 2011 Feb;41(2):175–84.
dc.source.bibliographicCitationLevy SE, Mandell DS, Merhar S, Ittenbach RF, Pinto-Martin JA. Use of complementary and alternative medicine among children recently diagnosed with autistic spectrum disorder. J Dev Behav Pediatr. LWW; 2003;24(6):418–23.
dc.source.bibliographicCitationJan JE, Hamilton D, Seward N, Fast DK, Freeman RD, Laudon M. Clinical trials of controlledrelease melatonin in children with sleep-wake cycle disorders. J Pineal Res. New York: Liss, c1984-; 2000;29(1):34–9.
dc.source.bibliographicCitationRepública de Colombia Ministerio de Salud y Protección Social Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA. RESOLUCIÓN No. 2015013919 DE 13 de Abril de 2015 Por la cual se concede un Registro Sanitario [Internet]. Bogotá: INVIMA; 2015 p. 1–3. Available from: http://web.sivicos.gov.co/registros/pdf/1287670_2015013919.pdf
dc.source.bibliographicCitationNeurim Pharmaceuticals. Circadin® 2mg (prolonged-release melatonin) is now commercially available in Colombia [Internet]. 2015 [cited 2016 Oct 16]. Available from: http://www.neurim.com/news/2015-10-01/circadin-2mg-prolonged-release-melatonin-is-nowcommercially-available-in-colombia/
dc.source.bibliographicCitationJohnson KP, Malow BA. Assessment and pharmacologic treatment of sleep disturbance in autism. Child Adolesc Psychiatr Clin N Am. Elsevier; 2008;17(4):773–85.
dc.source.bibliographicCitationMelke J, Botros HG, Chaste P, Betancur C, Nygren G, Anckarsäter H, et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry. Nature Publishing Group; 2008;13(1):90–8.
dc.source.bibliographicCitationReiter R, Tang L, Garcia JJ, Munoz-Hoyos A. Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci. ENGLAND; 1997;60(25):2255–71.
dc.source.bibliographicCitationChauhan A, Chauhan V. Oxidative stress in autism. Pathophysiology. Elsevier; 2006;13(3):171– 81.
dc.source.bibliographicCitationCohly HHP, Panja A. Immunological findings in autism. Int Rev Neurobiol. Elsevier; 2005;71:317–4
dc.source.bibliographicCitationEl-Sherif Y, Tesoriero J, Hogan M V, Wieraszko A. Melatonin regulates neuronal plasticity in the hippocampus. J Neurosci Res. United States; 2003 May;72(4):454–60.
dc.source.bibliographicCitationGolombek DA, Pevet P, Cardinali DP. Melatonin effects on behavior: possible mediation by the central GABAergic system. Neurosci Biobehav Rev. UNITED STATES; 1996;20(3):403–12.
dc.source.bibliographicCitationNiles LP, Pickering DS, Arciszewski MA. Effects of chronic melatonin administration on GABA and diazepam binding in rat brain. J Neural Transm. AUSTRIA; 1987;70(1-2):117–24.
dc.source.bibliographicCitationPandi-Perumal SR, Srinivasan V, Maestroni GJM, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: Nature’s most versatile biological signal? FEBS J. England; 2006 Jul;273(13):2813– 38.
dc.source.bibliographicCitationCampino C, Valenzuela FJ, Torres-Farfan C, Reynolds HE, Abarzua-Catalan L, Arteaga E, et al. Melatonin exerts direct inhibitory actions on ACTH responses in the human adrenal gland. Horm Metab Res = Horm und Stoffwechselforsch = Horm Metab. Germany; 2011 May;43(5):337–42.
dc.source.bibliographicCitationMalow B, Adkins KW, McGrew SG, Wang L, Goldman SE, Fawkes D, et al. Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord. United States; 2012 Aug;42(8):1729–37; author reply 1738.
dc.source.bibliographicCitationJan JE, O’Donnell ME. Use of melatonin in the treatment of paediatric sleep disorders. J Pineal Res. Wiley Online Library; 1996;21(4):193–9
dc.source.bibliographicCitationAndersen IM, Kaczmarska J, McGrew SG, Malow BA. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol. Canada; 2008 May;23(5):482–5.
dc.rights.ccAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/2.5/co/

 

Reconocimientos: